Skip to main navigation Skip to search Skip to main content

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy

  • Kern, Johannes (Primary Chief Investigator (PCI))
  • Frew, John W. (Chief Investigator (CI))
  • Hong, Esther (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date22/11/24 → 22/11/26

Keywords

  • clinical trial
  • pyoderma gangrenosum
  • spesolimab
  • Dermatology

Clinical Trial Phase

  • Phase III (a & b)